{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.2394","value":"-0.082"},{"groupId":"OG001","spread":"0.8363","value":"0.085"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"479"}],"units":"Participants"}],"title":"Fatigue, n=243,479"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7595","value":"1.673"},{"groupId":"OG001","spread":"0.4828","value":"3.115"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"479"}],"units":"Participants"}],"title":"Nausea/Vomiting, n=244,479"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.2274","value":"-0.195"},{"groupId":"OG001","spread":"1.0166","value":"0.765"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"480"}],"units":"Participants"}],"title":"Pain, n=244,480"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.3592","value":"0.644"},{"groupId":"OG001","spread":"0.8518","value":"1.347"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"479"}],"units":"Participants"}],"title":"Dyspnea, n=244,479"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.9882","value":"2.195"},{"groupId":"OG001","spread":"1.2791","value":"3.478"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"479"}],"units":"Participants"}],"title":"Insomnia, n=244,479"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.3987","value":"-0.827"},{"groupId":"OG001","spread":"2.3195","value":"-0.395"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Appetite Loss, n=8,30"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.5793","value":"-1.147"},{"groupId":"OG001","spread":"1.0446","value":"6.356"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"478"}],"units":"Participants"}],"title":"Constipation, n=244,478"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.8667","value":"9.335"},{"groupId":"OG001","spread":"2.0136","value":"-3.340"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Diarrhea, n=8,30"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.2978","value":"-5.058"},{"groupId":"OG001","spread":"0.9276","value":"-3.356"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"475"}],"units":"Participants"}],"title":"Financial Difficulties, n=243,475"}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"480"}],"units":"Participants"}],"description":"EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale, and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Symptom scale had total 7 items (fatigue-3, pain-2, nausea/vomiting-2). Each symptoms scales and 6 single additional symptoms items score was calculated by averaging scores of all scale items and transforming average scores linearly (\\[average score minus 1\\] divided by 3\\*100). All of the symptoms scales and 6 single additional symptoms scales range in score from 0 to 100. Higher score represents a higher (\"worse\") level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).","dispersionType":"Standard Error","groups":[{"description":"Participants received placebo matching niraparib 300 milligram (mg) (3×100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kilogram \\[kg\\] and Baseline platelet count \\>=150,000 per microliter \\[μL\\]) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG000","title":"Placebo"},{"description":"Participants received niraparib 300 mg (3×100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kg and Baseline platelet count \\>=150,000 per μL) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG001","title":"Niraparib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1, Pre-dose) and Up to Week 24","title":"Change From Baseline in Symptoms Scales and Symptoms Items (Dyspnea, Appetite Loss, Insomnia, Constipation, Diarrhea and Financial Difficulty) of EORTC-QLQ-C30","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}